Chlordiazepoxide
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Chlordiazepoxide: From Anxiety and Alcohol Withdrawal to Insomnia
One-Sentence Summary
Chlordiazepoxide is a benzodiazepine originally used for anxiety, alcohol withdrawal, and related conditions (including irritable bowel syndrome and peptic ulcer disease as listed in the knowledge graph). The TxGNN model predicts it may be effective for insomnia, but there are 0 registered clinical trials and only indirect literature (mostly reviews and older studies of other benzodiazepines or combination products) supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety, alcohol withdrawal, mixed anxiety and depressive disorder (the approved indication text in the Singapore licences is blank; these come from the knowledge graph) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.998% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, chlordiazepoxide is a benzodiazepine that positively modulates GABA-A receptors. This produces anxiolytic and sedative-hypnotic effects, and it is the same mechanism that underlies other benzodiazepines used for sleep problems.
Anxiety and insomnia often occur together, and anxiolytic sedation is a plausible bridge between the original indication and the predicted one. However, the literature retrieved is mostly indirect. It includes pharmacokinetic reviews of anxiolytics, reviews of benzodiazepine hypnotics in the elderly, a sleep-architecture comparison of a chlordiazepoxide/amitriptyline combination (Limbitrol) against amitriptyline, and a clobazam vs chlordiazepoxide comparison in alcohol withdrawal. No chlordiazepoxide-specific insomnia trial is present.
Safety concerns (dependence, falls, cognitive impairment in older adults) weigh against use, and shorter-acting agents are generally preferred for sleep.
Other predictions in the list are weaker. Barbiturate abuse (rank 7) has a credible rationale through GABA-A cross-tolerance and established use in withdrawal management, and it is the only one advanced to a research question. Cauda equina syndrome, obsolete neurogenic bladder, ADHD (inattentive type), antidepressant-type abuse, hallucinogen abuse, and myofascial pain syndrome have no or only speculative support. The single paper for specific developmental disorder is a preclinical study suggesting harm (learning deficits).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Publications retrieved for insomnia and the closely related sleep-initiation/maintenance disorder:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7595266 | 1995 | Review | J Fam Pract | Review of benzodiazepines for insomnia in community-dwelling elders; no long-term effectiveness studies, and injury risk was examined |
| 3536890 | 1986 | Double-blind randomized study | J Clin Psychiatry | Chlordiazepoxide-amitriptyline (Limbitrol) vs amitriptyline: faster symptom improvement with Limbitrol, no differences in sleep laboratory parameters |
| 22521806 | 2013 | Review | Eur Psychiatry | Critical reappraisal of the role of benzodiazepines in psychiatric disorders |
| 4365779 | 1974 | Comparative study | Br J Psychiatry | Compares the hypnotic effects of chlordiazepoxide and amylobarbitone sodium (no abstract available) |
| 2883822 | 1986 | Review | Acta Psychiatr Scand Suppl | Elderly people show a 2-3 fold greater response to benzodiazepines, not explained by plasma concentrations |
| 6137426 | 1983 | Randomized double-blind trial | J Int Med Res | Clobazam vs chlordiazepoxide in acute alcohol withdrawal (40 patients); both effective, clobazam better on anxiety scale (alcohol withdrawal, not insomnia) |
| 23330992 | 2013 | Review | Expert Opin Drug Metab Toxicol | Pharmacokinetics of anxiolytic drugs |
| 30680986 | 2019 | Cross-sectional | Med Glas (Zenica) | Prevalence of potentially inappropriate medications among Iranian older adults (Beers criteria) |
| 4628683 | 1972 | Clinical trial | Curr Ther Res | Molindone vs chlordiazepoxide in anxious outpatients |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN01907P | BENPINE TABLET 5 mg | Tablet, sugar coated | Not stated in the licence data |
| SIN08651P | CHLOBAX TABLET | Tablet, sugar coated | Not stated in the licence data |
| SIN03049P | AA PHARMA CHLORAX CAPSULE | Capsule | Not stated in the licence data |
All three are valid single-ingredient oral products.
Safety Considerations
Package insert warnings and contraindications were not available in the data compiled for this report; please refer to the package insert for these.
- Knowledge-graph contraindications (not label text): the graph links chlordiazepoxide to contraindications in several areas:
- Cardiovascular: hypertension, orthostatic hypotension, long QT syndrome, torsades de pointes
- Neurological and psychiatric: epilepsy, psychotic disorder, manic bipolar affective disorder
- Organ function: kidney disease, liver disease, gallbladder disease
- Metabolic and endocrine: porphyria, hypothyroidism
- Others: open-angle glaucoma, systemic lupus erythematosus
These should be verified against the official label.
- Drug Interactions: 100 interactions were found. The main ones shown are:
- Major: morphine (including liposomal morphine), consistent with additive CNS and respiratory depression.
- Moderate: bupropion, omeprazole, cimetidine, clarithromycin, dronabinol, metoclopramide, nabilone, opium, sibutramine, teduglutide.
- Minor: antacids such as aluminium hydroxide, calcium carbonate, magaldrate, and magnesium salts.
- Literature-based concerns: dependence and abuse liability, withdrawal syndrome, and falls/cognitive impairment in older adults.
Conclusion and Next Steps
Decision: Hold
Rationale: The insomnia prediction has a plausible GABA-A mechanism, but there are no registered trials and the literature is indirect, dated, or based on combination products. The benefit-risk profile (dependence, sedation, risks in older adults) is unfavourable compared with shorter-acting alternatives. The remaining predictions have no or only speculative support.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (currently a blocking data gap)
- Detailed mechanism of action data from DrugBank
- Controlled trial data specific to chlordiazepoxide in insomnia, with comparison against shorter-acting hypnotics
- A dependence and older-adult risk mitigation plan
- Optionally, a separate research question on barbiturate or sedative-hypnotic withdrawal, the only other prediction with a credible mechanistic rationale
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.